Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Carbohydrate doai
Reexamination Certificate
2009-07-20
2011-11-29
McGarry, Sean (Department: 1635)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Carbohydrate doai
C536S023100, C536S024100, C536S024500, C435S375000
Reexamination Certificate
active
08067389
ABSTRACT:
The present application is directed to siRNA-based silencing of the type II receptor of TGFβ. siRNAs that target this receptor abrogate the receptor protein and transcript, TGFβ-mediated processes such as fibronectin assembly and cell migration also are inhibited and the molecules of the invention are efficacious in reducing the inflammatory response and matrix deposition. These findings show that siRNAs can be successfully delivered both in vitro and in vivo to regulate the TGFβ type II receptor level and modulate wound response. Methods and compositions exploiting the findings of the present invention have a wide-ranging application, extending from treatment of disorders of the eye to other organs and tissues throughout the body.
REFERENCES:
patent: 7148342 (2006-12-01), Tolentino et al.
patent: 7345027 (2008-03-01), Tolentino et al.
patent: 2003/0064944 (2003-04-01), Murray et al.
patent: 2004/0229266 (2004-11-01), Tuschl et al.
patent: 2005/0227936 (2005-10-01), McSwiggen et al.
patent: 2005/0287128 (2005-12-01), Guerciolini et al.
patent: 2007/0031844 (2007-02-01), Khvorova et al.
patent: WO 03/070197 (2003-08-01), None
patent: WO 2005/031002 (2005-04-01), None
Vickers et al., The Journal of Biological Chemistry vol. 278(9):7108-7118, 2003.
Arias et al., “Adenoviral Delivery of an Antisense RNA Complementary to the 3′ Coding Sequence of Transforming Growth Factor-β1 Inhibits Fibrogenic Activities of Hepatic Stellate Cells1”, Cell Growth & Differentiation 2002 13:265-273.
Cordeiro et al., Novel antisense oligonucleotides targeting TFG-β inhibit in vivo scarring and improve surgical outcome, Gene Therapy 2003 10:59-71.
Elbashir et al., “Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells”, Nature 2001 411:494-498.
Fire et al., “Potent and specific genetic interference by double-stranded RNA inCaenorhabditis elegans”, Nature 1998 391:806-811.
Hannon, Gregory J., “RNA interference”, Nature 2002 418:244-251.
Reich et al., “Small interfering RNA (siRNA) targetingVEGFeffectively inhibits ocular neovascularization in a mouse model”, Molecular Vision 2003 9:210-216.
Shen et al., “Specific inhibition of transforming growth factor-β2 expression in human osteoblast cells by antisense phosphorothioate oligonucleotides”, Eur. J. Biochem. 2001 268:2331-2337.
Song et al., “RNA interference targeting Fas protects mice from fulminant hepatitis”, Nature Medicine 2003 9(3):347-351.
Su et al., “Ribozyme to Human TGF-β1 mRNA Inhibits the Proliferation of Human Vascular Smooth Muscle Cells”, Biochemical and Biophysical Research Communications 2000 278:401-407.
Yamamoto et al., “Ribozyme Oligonucleotides Against Transforming Growth Factor-β Inhibited Neointimal Formation After Vascular Injury in Rat Model”, Circulation 2000 102:1308-1314.
NCBI Genbank Accession M85079 [gi:339569] Jul. 31, 1992-Jan. 14, 1995 with Revision History.
Iyer et al., “Targeting TGFβ Signaling for Cancer therapy”, Cancer Biology &Therapy 2005 4:3, 261-266.
Lin et al ., “Expression Cloning of the TGF-β Type II Receptor, a Functional Transmembrane Serine/Threonine Kinase”, Cell 1992 68:775-785.
Tuschl et al., “Selection of siRNA duplexes from the target mRNA sequence”, The siRNA user guide Apr. 16, 2003, 6 pages.
Caplen et al. “Specific Inhibition of Gene Expression by Small Double-Stranded RNAs in Invertebrate and Vertebrate Systems”, Proceedings of the National Academy of Science 2001 vol. 98(17): 9742-9747.
Nakamura et al. “RNA Interference Targeting Transforming Growth Factor-β Type II Receptor Suppresses Ocular Inflammation and Fibrosis”, Molecular Vision 2004 vol. 10: 703-711.
Search Report from Corresponding EPO Application No. 04780766.4, Jun. 1, 2010.
Kumar Nalin M.
Malik Asrar B.
Pulido Jose S.
Siddiqui Shahid
Yue Beatrice
Licata & Tyrrell P.C.
McGarry Sean
The Broad of Trustees of the University of Illinois
LandOfFree
Silencing of TGFβ type II receptor expression by siRNA does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Silencing of TGFβ type II receptor expression by siRNA, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Silencing of TGFβ type II receptor expression by siRNA will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4257017